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The precise regulation of many alternative splicing (AS) events by specific splicing factors is essential to
determine tissue types and developmental stages. However, the molecular basis of tissue-specific AS
regulation and the properties of splicing regulatory networks (SRNs) are poorly understood. Here we
comprehensively predict the targets of the brain- and muscle-specific splicing factor Fox-1 (A2BP1) and its
paralog Fox-2 (RBM9) and systematically define the corresponding SRNs genome-wide. Fox-1/2 are conserved
from worm to human, and specifically recognize the RNA element UGCAUG. We integrate Fox-1/2-binding
specificity with phylogenetic conservation, splicing microarray data, and additional computational and
experimental characterization. We predict thousands of Fox-1/2 targets with conserved binding sites, at a false
discovery rate (FDR) of ∼24%, including many validated experimentally, suggesting a surprisingly extensive
SRN. The preferred position of the binding sites differs according to AS pattern, and determines either
activation or repression of exon recognition by Fox-1/2. Many predicted targets are important for
neuromuscular functions, and have been implicated in several genetic diseases. We also identified instances of
binding site creation or loss in different vertebrate lineages and human populations, which likely reflect
fine-tuning of gene expression regulation during evolution.
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The sequencing of complete genomes revealed that com-
plex metazoans, including mammals, have only slightly
more genes than unicellular yeast (International Human
Genome Sequencing Consortium 2001). Organismal
complexity must have resulted largely from mechanisms
for diversifying the expression products, and the tempo-
ral and spatial patterns, from a limited set of genes. It is
crucial to understand how gene expression is orches-
trated to determine developmental stages, specify cell
types, and respond to external stimuli (Maniatis and
Reed 2002). Alternative splicing (AS), the process for re-
moving introns from pre-mRNA transcripts and joining
exons in different combinations, is an essential step of
post-transcriptional regulation (Cartegni et al. 2002;
Black 2003). In mammals, more than two-thirds of genes
are alternatively spliced (Johnson et al. 2003). The choice
of exons and splice sites is largely determined by many
RNA-binding proteins, or splicing factors, which inter-
act with cis-regulatory elements to activate or repress
particular splicing events.
Many splicing factors have restricted and dynamic ex-
pression patterns, and play important roles in tissue-spe-
cific or developmentally regulated splicing of particular
transcripts. However, the mechanisms and impact of
these AS events remain poorly understood. A well-stud-
ied example is Sxl, Tra, Tra-2, and several other splicing
factors in Drosophila, which regulate a cascade of AS
events to control sex determination (Lopez 1998). In
mammals, tissue-specific splicing factors include Nova-
1/2, PTB/nPTB, Fox-1/2, Muscleblind-like (MBNL) and
CELF family proteins, Hu proteins, TIA1/TIAR, and
probably many more yet to be characterized (for reviews,
see Li et al. 2007; David and Manley 2008). The identifi-
cation of the RNA targets of these factors is critical for
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understanding the splicing regulatory networks (SRNs),
but remains challenging; in most cases, only a handful of
targets have been determined experimentally. Recently,
the development of high-throughput technologies that
monitor mRNA isoform abundances and protein–RNA
interactions, including splicing microarrays (Johnson et
al. 2003; Ule et al. 2005b; Sugnet et al. 2006; Boutz et al.
2007b), RNP immunoprecipitation-microarray (RIP-Chip)
(Keene et al. 2006), and ultraviolet cross-linking and im-
munoprecipitation (CLIP) assays (Ule et al. 2005a), pro-
vided new opportunities to identify in vivo RNA targets
and characterize SRNs genome-wide (for reviews, see
Blencowe 2006; Moore and Silver 2008). This has been
demonstrated already in studies of Nova-1/2 targets,
which revealed important functions of coregulated tar-
gets in the neuronal synapse and in axon guidance, as
well as mechanisms by which Nova-1/2 activate or re-
press exon inclusion, depending on the locations of their
binding sites (Ule et al. 2006). Other studies described
subsets of exons with splicing patterns characteristic of
particular tissues, or associated with responses to certain
stimuli; these exons sometimes show enrichment of
RNA sequence motifs and Gene Ontology (GO) terms,
suggesting coordinated splicing regulation that could be
important for cellular functions (Sugnet et al. 2006; Das
et al. 2007; Fagnani et al. 2007; Ip et al. 2007; McKee et
al. 2007). However, more detailed studies are required to
identify individual targets for particular splicing factors.
Computational target prediction for specific splicing
factors is difficult, largely due to the small size and de-
generacy of splicing-factor-binding motifs. An exception
to this degeneracy is the hexanucleotide UGCAUG,
which is an important intronic element for the splicing
of several exons (Huh and Hynes 1994; Kawamoto 1996;
Lim and Sharp 1998). A computational study further sug-
gested that this element is enriched in the introns down-
stream from a set of neuron-specific exons (Brudno et al.
2001). Importantly, the zebrafish and mammalian ho-
mologs of Caenorhabditis elegans fox-1 were identified
as recognizing the (U)GCAUG element (Jin et al. 2003;
Ponthier et al. 2006). In C. elegans, the fox-1 gene is
critical in the sex determination pathway for X-chromo-
some dosage compensation (Meyer 2000). In mammals,
Fox-1 (also known as A2BP1) encodes an RNA-binding
protein initially identified as an interacting partner of
ataxin-2, and has at least one paralog, Fox-2 (also known
as RBM9 or Fxh) (Nakahata and Kawamoto 2005). Hu-
man Fox-1 and Fox-2 share very high sequence homol-
ogy—100% identity in the RRM domain—and bind to
the same RNA element (Supplemental Fig. S1; Kiehl et
al. 2001; Jin et al. 2003; Auweter et al. 2006; Ponthier et
al. 2006). Both proteins are exclusively or preferentially
expressed in brain, heart, and skeletal muscle. In addi-
tion, mutation or abnormal expression of Fox-1 has been
found in patients with several genetic diseases, including
epilepsy, mental retardation (Bhalla et al. 2004), autism
(The Autism Genome Project Consortium 2007; Martin
et al. 2007; Sebat et al. 2007), and heart disease (Kaynak
et al. 2003). Fox-2 was also implicated in hormone sig-
naling, as a corepressor of tamoxifen activation of the
estrogen receptor (Norris et al. 2002). Therefore, Fox-1/2
are likely essential regulators for tissue-specific splicing,
and systematic analysis of their targets may provide im-
portant insights into the mechanisms of tissue-specific
splicing regulation, the characteristics of SRNs, and
their physiological roles.
In this study, we define and characterize the SRNs of
Fox-1/2. We combined computational predictions from
comparative genomics analysis, with experimental vali-
dation and characterization. Strikingly, our analysis re-
vealed thousands of potential Fox-1/2 targets with bind-
ing sites highly conserved across vertebrate species. Fox-
1/2 can either activate or repress splicing, depending on
the locations of their binding sites, and also contribute to
more complex splicing patterns. Many of the predicted
targets play important roles in neuromuscular functions
and disorders. We also discuss the evolution of Fox-1/2-
binding sites across different vertebrate lineages and
among different human populations, and the potential
phenotypic implications.
Results
Comparative genomics analysis defines extensive
Fox-1/2 SRNs with high specificity
Several previous studies found the enrichment of the
UGCAUG element in conserved intronic sequences
flanking brain-specific exons or conserved alternative ex-
ons (Brudno et al. 2001; Minovitsky et al. 2005; Sugnet et
al. 2006; Voelker and Berglund 2007; Yeo et al. 2007), but
it was unclear if the sequence specificity and conserva-
tion are sufficient to predict Fox-1/2 targets. To charac-
terize global features of SRNs, we sought to develop an
effective method for genome-wide Fox-1/2 target predic-
tion. We searched all human internal exons, and 200
nucleotides (nt) of upstream and downstream intronic
flanking (UIF and DIF) regions for conserved UGCAUG
elements, taking advantage of 28 sequenced vertebrate
genomes (Miller et al. 2007). The inclusion of many spe-
cies for comparison, in contrast to previous studies (Mi-
novitsky et al. 2005; Voelker and Berglund 2007; Yeo et
al. 2007), was justified by their power in reducing the
false-positive rate in pairwise species analysis (Supple-
mental Fig. S2; see also Supplemental Material). To ac-
count for the different levels of divergence among the
vertebrate genomes, we adapted a branch length score
(BLS) method (Stark et al. 2007) to measure the conser-
vation level of each UGCAUG element, as summarized
in Supplemental Figure S3. Several examples of elements
with different levels of conservation, along with their
BLS scores, are shown below (see Fig. 6C, below). The
false discovery rate (FDR) associated with each BLS score
was then determined using shuffled random motifs as
controls.
To determine appropriate BLS thresholds, we initially
studied cassette exons, the most frequent form of AS in
mammals (Thanaraj et al. 2004). The conserved fraction
of Fox-1/2 sites in UIF and DIF sequences is higher than
that of random sites for the whole range of BLS thresh-
olds (Fig. 1A, left and right panels), which confirms and
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extends previous observations (Brudno et al. 2001; Mi-
novitsky et al. 2005; Voelker and Berglund 2007; Yeo et
al. 2007). Importantly, the comparative analysis of many
vertebrate species makes it possible to achieve very low
FDRs. Excess Fox-1/2 site conservation in the exons was
observed only when we applied very stringent BLS
thresholds, which correspond to conservation beyond
mammals (Fig. 1A, middle panel; Supplemental Fig.
S2B). As a trade-off between sensitivity and specificity of
target prediction, we required a BLS threshold of 0.22 for
UIF and DIF sites, corresponding to an FDR of 0.24 and
0.15, respectively; for exonic sites, a BLS threshold of
0.8 was required to achieve comparable specificity
(FDR = 0.24) (Fig. 1A, indicated by arrowheads).
We then applied these thresholds to all human inter-
nal exons, and predicted 1706 target exons (1457 after
overlapping exon variants were merged) from 1103
genes, with at least one conserved Fox-1/2-binding site
(FDR = 24%) (Supplemental Table S1). This includes 192
exons with two or more sites in the same or different
regions (FDR = 0.03). Compared with 10 known Fox-1/2
targets determined by previous studies, our predictions
successfully included six; the other four were missed be-
cause their binding sites are too far away from the exons
or do not reach the conservation level we required, or the
exon was not included in our database (Supplemental
Table S2).
The predicted Fox-1/2 target exons have a number of
characteristics similar to those of known regulated tis-
sue-specific exons. Overall, 757 exons are alternatively
spliced (Fig. 1B, left panel), and this proportion is signifi-
cantly higher than the overall fraction of AS exons (Fig.
1B, right panel) in the human genome (44.4% vs. 25.7%,
P = 5 × 10−63). Among predicted targets with AS are 544
cassette exons (including some with multiple types of
AS), which is a significant over-representation, com-
pared with the expected proportion estimated from all
AS exons (48.6% vs. 29.6%, P = 1.4 × 10−27). A more
stringent comparison to exons with conserved random
motifs gave qualitatively similar results (data not
shown). Importantly, the AS exons predicted as Fox-1/2
targets, and cassette exons in particular, have more con-
served AS patterns in mouse/rat (50.7% vs. 10%–20%)
(Blencowe 2006), smaller exon sizes (75 nt vs. 110 nt
median), and a higher tendency to preserve the reading
frame (67.5% vs. 42%), compared with all cassette ex-
ons, consistent with previous observations from tissue-
specific exons (Blencowe 2006; Sugnet et al. 2006; Fag-
nani et al. 2007). We expect that the proportion of AS
exons we observed is an underestimate, because many
AS exons with low EST coverage may be misclassified as
constitutive exons. Among the exons currently without
evidence of AS, 83 (8.7%) have mouse and/or rat ortholo-
gous exons associated with AS events, and 176 (18.5%)
are predicted as alternative conserved exons (ACEs) (Yeo
et al. 2005). In summary, comparative analysis of mul-
tiple genomes provides an effective way to predict func-
tional Fox-1/2 targets.
Different types of AS events correlate with distinct
patterns of Fox-1/2 motif distribution
Since all typical types of alternative exons and splice
sites are present in our predicted Fox-1/2 targets, we ex-
amined the distribution of Fox-1/2-binding sites sepa-
rately for each type. We found that the positional pref-
erence of Fox-1/2-binding sites differs among different
types of AS events. For cassette exons, conserved Fox-1/
2-binding sites are 1.75-fold more enriched in the DIF vs.
the UIF region (Fig. 1C), in contrast to the approximately
equal enrichment for conserved random sites
(P = 1.8 × 10−8). No preference for the UIF and DIF re-
gions was observed in the case of mutually exclusive or
constitutive exons (Fig. 1D,G). Interestingly, for exons
Figure 1. Comparative analysis accurately predicts Fox-1/2
targets. (A, left axis) The number of conserved Fox-1/2-binding
sites (blue) and random-motif sites (gray) in UIF (left), exonic
(middle), and DIF (right) sequences of cassette exons, using
varying thresholds of BLSs. Error bars represent standard error of
the mean. (Right axis) The corresponding FDR of prediction is
shown in red. The thresholds used in the paper (0.22 for UIF and
DIF sites and 0.8 for exonic sites) are indicated by arrowheads.
(B) Proportions of different types of splicing patterns for pre-
dicted Fox-1/2 targets (left) and all internal exons (right). (C–G)
Distribution of conserved Fox-1/2-binding sites in different re-
gions for cassette exons (C), mutually-exclusive exons (D), al-
ternative 5 splice sites (E), and 3 splice sites (F), and constitu-
tive exons (G). In each panel, the splicing pattern is shown sche-
matically above the histogram. The distribution of conserved
Fox-1/2 sites is color-coded as in B. The distribution of con-
served random-motif sites is shown in gray for comparison.
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with alternative 5 and 3 splice sites, conserved Fox-1/2
sites tend to be more enriched in the intron involved in
alternative splice site selection (Fig. 1E,F). This is par-
ticularly true for alternative 5 splice sites, for which the
DIF region has 3.9-fold more putative binding sites than
the UIF region (P = 2.7 × 10−5) (Fig. 1E). This preference is
only partly explained by the generally higher level of
sequence conservation in intronic sequences regulating
alternative splice site selection. As another line of evi-
dence, we examined the distribution of Fox-1/2-binding
sites for all exons with alternative 5 or 3 splice sites,
without requiring cross-species conservation. Again, a
different positional preference was observed, with 1.2-
fold more DIF sites for alternative 5 splice sites and
slightly more UIF sites for alternative 3 splice sites
(P = 0.004). The preference for Fox-1/2 sites to be located
near alternative splice sites suggests that Fox-1/2 may
play an important role in the differential selection of
alternative splice sites in a tissue-specific manner.
Splicing patterns of Fox-1/2 targets across tissues
suggest position-dependent and combinatorial
regulation
We next asked how Fox-1/2 enhance or repress target
splicing depending on the location of the presumptive
binding sites. To address this question in an unbiased
manner, we examined the splicing patterns of predicted
Fox-1/2 targets in a panel of 47 tissues and cell lines
(Supplemental Table S3), as measured using prototype
splicing microarrays. This microarray platform includes
both exon and exon-junction probes, which interrogate
constitutively and alternatively spliced regions detected
from EST/cDNA data, and can therefore monitor the ex-
pression of both genes and individual mRNA isoforms
genome-wide (J.C. Castle, C. Zhang, J.K. Shah, A.V.
Kulkarni, T.A. Cooper, and J.M. Johnson, in prep.).
The splicing microarray was designed independently
of this study for a different purpose. Therefore, among
the 544 cassette exons we predicted as Fox-1/2 targets,
only 234 exons are represented on the array (Fig. 2A;
Supplemental Table S4). For each of these exons, we used
a splicing index to measure the reciprocal change of exon
inclusion level in each particular condition, relative to a
reference pool (Ule et al. 2005b). Hierarchical clustering
of tissues using the splicing data successfully grouped
brain, muscle, and heart tissues in one cluster, and other
tissues in the other cluster, consistent with the restric-
tive or preferential expression of Fox-1/2 in the first
group (Fig. 2A,B).
A majority (62%) of the cassette exons showed higher
inclusion in brain, heart, and skeletal muscles, compared
with other tissues (P = 0.0004). Correlating with a 1.6-
fold enrichment of predicted Fox-1/2 sites in the DIF
Figure 2. Splicing profiling of predicted
Fox-1/2 targets shows position-dependent
and complex modes of Fox-1/2-mediated
splicing regulation. (A) Hierarchical clus-
tering of splicing indices of 234 cassette
exons predicted as Fox-1/2 targets in 47
human tissues and cell lines (for color
scale, see bottom of B). The tissue cluster
on the right includes brain, heart, and
skeletal muscle tissues is labeled. For each
exon, the number of conserved Fox-1/2-
binding sites in UIF, exonic, and DIF se-
quences is gray-scale coded on the right, in
the same order as in the splicing heatmap
(grayscale on the right). Four clusters of
exons, with different combinations of
splicing levels in brain and heart/muscle,
are labeled by dashed boxes. (B) The ex-
pression pattern of Fox-1/2 in the same or-
der of tissues as in the splicing heatmap
(color scale at the bottom). (C–G) Average
splicing profile (left) and distribution of
conserved Fox-1/2 sites (right) for all 234
predicted targets (C) and exons belonging
to the four clusters (D–G). (H, left) The av-
erage splicing profile of all cassette exons
on the splicing microarrays as controls.
(Right) The distribution of random-motif
sites for all cassette exons was used to test
the enrichment/depletion of Fox-1/2 sites
in different regions for exon subsets in
C–G. The P-values from 2 tests are also
indicated in (C–G).
Splicing regulatory network of Fox-1/2
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region vs. the UIF region, DIF sites were generally asso-
ciated with inclusion of the upstream exon (Fig. 2C),
confirming and extending several previous studies (Jin et
al. 2003; Underwood et al. 2005; Sugnet et al. 2006; Das
et al. 2007).
We further examined four exon clusters with different
combinations of splicing patterns in brain and heart/
skeletal muscle tissues: (1) exons specifically included in
both brain and heart/muscle (B[+]M[+]); (2) exons specifi-
cally included only in brain (B[+]M[−]); (3) exons specifi-
cally skipped in brain and muscle/heart (B[−]M[−]); and
(4) exons specifically skipped in brain (B[−]M[+]) (Fig. 2A).
We reasoned that exons mainly regulated by Fox-1/2
should have consistent splicing patterns in brain and
heart/muscle, because Fox-1 and Fox-2 have high expres-
sion in these tissues. Therefore, focusing on the B[+]M[+]
and B[−]M[−] clusters should minimize complications
due to other factors, and help to infer the rules for Fox-
1/2-mediated splicing, as influenced by the locations of
the binding sites. Indeed, these two clusters have very
distinct spatial distributions of putative Fox-1/2-binding
sites (Fig. 2D,F). The B[+]M[+] cluster (Fig. 2D) shows a
very strong tendency for the sites being located in the
DIF region, rather than the UIF region (sixfold enrich-
ment, P = 0.007, compared with random motif sites) (Fig.
2H). This bias suggests that downstream Fox-1/2-binding
sites are potent splicing enhancers in general. In con-
trast, for the B[−]M[−] cluster, we observed an opposite
pattern of Fox-1/2-binding site distribution, with a nine-
fold enrichment in the UIF region (Fig. 2F) (P = 0.0007,
compared with random motif sites). This in turn
strongly suggests that upstream binding sites repress
exon inclusion. Therefore, our analysis provides strong
evidence that the different effects of Fox-1/2 in splicing
regulation generally depend on the locations of the bind-
ing sites.
The other two clusters are also intriguing and indica-
tive of combinatorial regulation. In addition to Fox-1/2,
other splicing factors may play an important role in tis-
sue-specific splicing of these exons. For example, for the
exons in the B[−]M[+] cluster (Fig. 2G), Fox-1/2-binding
sites are significantly enriched in the DIF region
(P = 4 × 10−5), to an extent similar to that observed in the
B[+]M[+] cluster. However, these exons show very low
inclusion in brain. This pattern could be explained by
brain-specific repressors that counteract the enhancing
effects of Fox-1/2, or by muscle/heart-specific coactiva-
tors that promote exon inclusion together with Fox-1/2.
To confirm the splicing patterns observed from the
splicing microarrays, we performed semiquantitative
RT–PCR assays of several endogenous transcripts. In all
six cases we tested, cassette exons with conserved down-
stream intronic sites (FMNL3, PTBP2, and UAP1)
showed brain- and/or muscle/heart-specific exon inclu-
sion, whereas those with only conserved upstream in-
tronic sites (PB1, two exons from MBNL1) showed brain-
and/or muscle/heart-specific skipping (Fig. 3). Of par-
ticular interest is the UAP1 exon, which was included in
muscle and heart, but predominantly skipped in brain,
despite the presence of multiple downstream binding
sites. Different exon-inclusion levels in brain and
muscle/heart were also observed for MBNL1 exons. The
splicing patterns observed by RT–PCR are generally con-
sistent with those observed with the splicing microar-
rays, although a quantitative assessment will require ad-
ditional experiments. More importantly, the results sup-
port the idea that Fox-1/2 alone are not always sufficient
to determine the tissue-specific splicing pattern of target
genes.
Overexpression and knockdown of Fox-1/2 alter
the splicing of predicted Fox-1/2 targets depending
on the presence of the UGCAUG element
To validate the predicted targets and the position-depen-
dent effect of Fox-1/2-binding sites more directly, we
next tested the splicing of endogenous pre-mRNAs in
the presence or absence of Fox-1/2 proteins. We first ex-
amined Fox-1/2 expression in several cell lines by West-
ern blotting. In all the cell lines we tested, including a
few neuronal cell lines, we found variable levels of Fox-2
protein, but no Fox-1 (data not shown). Because RNAi is
very effective in HeLa cells, which express a low but
readily detectable level of Fox-2, we used this cell line to
test for AS of our predicted targets. For comparison, we
generated HeLa cell derivatives expressing different
combinations of Fox-1/2—i.e., neither Fox-1 nor Fox-2,
Fox-1 only, Fox-2 only, and both Fox-1 and Fox2—by
stable transduction of shRNAs targeting Fox-1 or Fox-2,
and/or Fox-1/2 cDNAs in retroviral vectors. Initial ex-
amination using several predicted targets showed that
expression of either Fox-1 or Fox-2 robustly changed
splicing of target exons, compared with the cells without
Fox-1/2, in a way similar to that in cells expressing both
Figure 3. RT–PCR analysis of predicted cassette exons shows
brain- and/or heart/muscle-specific splicing. Exon inclusion
level was measured in six human tissues by radioactive RT–
PCR. In each panel, the quantified exon inclusion level and the
number of conserved UIF, exonic, and DIF UGCAUG elements
are indicated above and below the gene symbol, respectively.
The size of each PCR product is also indicated.
Zhang et al.
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proteins (Supplemental Fig. S4A,B). Therefore, for sim-
plicity, we focused on three derivatives expressing no
Fox-1/2 (Fig. 4A, lane 1), Fox-2 only (Fig. 4A, lane 2), and
Fox-1 only (Fig. 4A, lane 3) for more extensive validation.
From our list of predicted targets, we chose to test
those with binding sites with a wide range of conserva-
tion scores, but favored genes involved in gene expres-
sion regulation, such as transcription and RNA process-
ing, and with links to genetic diseases. Among 33 tested
cassette exons with conserved downstream intronic sites
and detectable expression in HeLa cells, 18 (55%) clearly
gave a higher level of exon inclusion in the presence of
Fox-1 or Fox-2 (Fig. 4B; Supplemental Fig. S5; Supple-
mental Table S5), whereas the rest did not show a dis-
cernible change; none of them gave a reduction in exon
inclusion. Among the 22 tested cassette exons with only
conserved upstream intronic sites, 13 (59%) showed a
clear change of inclusion level when Fox-1 or Fox-2 was
expressed (Fig. 4C; Supplemental Fig. S6; Supplemental
Table S5). With the exception of PLOD2, all of these
exons (12 of 13) were repressed by Fox-1/2. These results
suggest a satisfactory validation rate of 55%–60%, given
the fact that we started from pure computational predic-
tions. Consistent with the splicing microarray data,
these analyses strongly indicate the enhancer character
of downstream intronic sites, and silencer character of
upstream intronic sites, that are predictive of Fox-1/2-
regulated splicing.
We next tested if Fox-1/2-regulated splicing depends
on the presence of UGCAUG element(s). To this end, we
generated two minigene constructs: one from the
FMNL3 gene (Fig. 5A) and the other from the PB1 gene
(Fig. 5C). The FMNL3 minigene comprises the two con-
stitutive exons flanking the cassette exon and both in-
trons (Fig. 5A). Inclusion or skipping of the cassette exon
results in the use of different stop codons. In the wild-
type minigene, there are four conserved Fox-1/2 sites
downstream from the cassette exon. The exon inclusion
level greatly increased when Fox-1 was overexpressed,
recapitulating the splicing pattern of the endogenous
gene (Fig. 5B, lanes 1,2). In contrast, Fox-1-mediated exon
inclusion became much weaker or completely disap-
peared when two of the sites (Fig. 5B, lanes 3,4 with mu-
tations in sites 1 and 2, lanes 6,7 with mutations in sites 3
and 4) or all four sites (Fig. 5B, lanes 7,8) were mutated.
The PB1 minigene is a chimeric construct consisting
of the PB1 cassette exon with partial flanking introns
(∼250 nt from the upstream and downstream introns,
respectively) inserted into intron 1 of a human -globin
gene splicing reporter (Fig. 5C). There are three con-
served Fox-1/2 sites upstream of the cassette exon. As
shown in Figure 5D, overexpression of Fox-1 strongly
inhibited inclusion of the cassette exon (lanes 1,2). When
we mutated one or more of the UGCAUG sites, the
inhibitory effect of Fox-1 was reduced or eliminated
(Fig. 5D, lanes 3–10). Therefore, Fox-1/2-mediated AS of
both FMNL3 and PB1 genes depends on the presence of
UGCAUG elements.
Predicted Fox-1/2 targets are enriched in genes
with neuromuscular functions
The large number of predicted targets raises the impor-
tant question of how the Fox-1/2 SRNs are organized to
perform cellular functions. To achieve a better under-
standing of the SRNs, we examined GO terms enriched
in the predicted Fox-1/2 target genes, in comparison with
a control gene set derived from exons with a similar con-
servation level (see Materials and Methods). Many Fox-
1/2 target genes have neuromuscular functions, which is
reflected in top GO terms related to cytoskeleton orga-
nization, ion channels, protein phosphorylation, muscle
contraction, etc. (Table 1). Some of these GO terms were
identified previously from smaller sets of brain/muscle-
Figure 4. RT–PCR analysis after stable Fox-
1/2 overexpression and knockdown in HeLa
cells validates predicted targets. (A) Sche-
matic representation of experimental valida-
tion in control or transduced HeLa cells. Con-
trol HeLa cells express Fox-2 but not Fox-1.
Two other transductant pools without Fox-
1/2 expression or with only Fox-1 expression
were generated by stable retroviral transduc-
tion with an shRNA against Fox-2 (shFox-2),
or with a combination of shRNA against
Fox-2 and stable transfection of Fox-1 cDNA
(shFox-2 + Fox-1). The expression of Fox-1 or
Fox-2 was confirmed by Western blotting
analysis using antibodies specific for each
protein. (Lane 1) HeLa cells with shRNA
knockdown of Fox-2. (Lane 2) untreated HeLa cells. (Lane 3) HeLa cells with shRNA knockdown of Fox-2 and stable transduction of
Fox-1 cDNA. (B,C) Radioactive RT–PCR analysis of predicted Fox-1/2 targets with downstream intronic binding sites (B), or with only
upstream intronic binding sites (C). All examples are cassette exons. For each exon, the gene symbol is shown below, together with
the number of conserved Fox-1/2-binding sites in UIF, exonic, and DIF sequences. In each panel, the quantified exon-inclusion level
and the number of conserved UIF, exonic, and DIF UGCAUG elements are indicated above and below the gene symbol, respectively.
The size of each PCR product is also labeled. For some of the genes, indicated by an asterisk, the splicing pattern in tissues was also
measured by RT–PCR, as shown in Figure 3.
Splicing regulatory network of Fox-1/2
GENES & DEVELOPMENT 2555
 Cold Spring Harbor Laboratory Press on November 3, 2017 - Published by genesdev.cshlp.orgDownloaded from 
specific exons, or exons with UGCAUG elements (Das
et al. 2007; Fagnani et al. 2007; Yeo et al. 2007), likewise
suggesting similar functions of many predicted targets.
Consistently, disruptions of our predicted Fox-1/2 tar-
get genes were previously implicated in neurological,
neurodegenerative, and sensory disorders, as well as heart
Table 1. Representative GO functions of predicted Fox-1/2 target genes
GO term Count P-value Fold change FDR (Benjamini)
Biological process
Cytoskeleton organization and biogenesis 68 1.1E−11 2.4 3.7E−08
Actin filament-based process 37 6.5E−09 2.9 1.1E−05
Potassium ion transport 31 1.7E−07 2.9 1.1E−04
Metal ion transport 56 2.0E−07 2.1 1.1E−04
Ion transport 91 3.0E−07 1.7 1.4E−04
Cation transport 65 2.2E−06 1.8 9.0E−04
System development 61 2.6E−06 1.9 9.6E−04
Nervous system development 59 8.3E−06 1.8 2.1E−03
Muscle contraction 28 1.8E−05 2.5 4.3E−03
Protein amino acid phosphorylation 70 4.2E−05 1.6 6.9E−03
Cellular component
Cytoskeleton 123 2.5E−15 2.1 1.5E−12
Actin cytoskeleton 51 1.2E−13 3.2 3.5E−11
Non-membrane-bound organelle 148 7.1E−09 1.6 1.1E−06
Myofibril 15 3.2E−08 5.9 3.9E−06
Synapse 30 9.2E−08 3.0 9.4E−06
Myosin 18 8.0E−07 4.0 7.0E−05
Sarcomere 13 1.0E−06 5.5 6.7E−05
Microtubule-associated complex 24 1.7E−06 3.1 9.7E−05
Striated muscle thick filament 9 9.1E−06 7.1 4.3E−04
A band 9 9.1E−06 7.1 4.3E−04
Post-synaptic membrane 18 8.8E−05 2.9 3.6E−03
Golgi-associated vesicle membrane 9 5.3E−04 4.5 1.9E−02
Molecular function
Cytoskeletal protein binding 79 4.4E−19 3.0 1.1E−15
Actin binding 55 2.0E−13 3.0 1.6E−10
Motor activity 38 1.4E−12 3.7 8.8E-10
Calmodulin binding 37 2.4E−12 3.8 1.2E−09
Ion channel activity 53 3.0E−07 2.1 1.0E−04
Enzyme binding 35 2.3E−06 2.4 5.6E−04
Figure 5. Fox-1/2-mediated splicing regulation de-
pends on the UGCAUG elements. (A) Schematic
representation of the FMNL3 minigene, which has
four natural copies of putative Fox-1/2-binding sites
(labeled 1–4) in DIF sequences. Different use of stop
codons due to AS is also indicated by red circles. The
conservation pattern of the region is displayed under
the diagram. (B) Splicing of the FMNL3 minigene
cassette exon in the wild-type minigene, without or
with Fox-1 protein, is shown in lanes 1 and 2, re-
spectively. Lanes 3–8 show the splicing of the mu-
tant minigenes. Mut12 (lanes 3,4) has mutations in
sites 1 and 2, and similarly for Mut34 (lanes 5,6) and
Mut 1234 (lanes 7,8). The quantified exon inclusion
level is indicated. The expression level of Fox-1 was
confirmed by Western blotting, as shown at the bot-
tom. (C) Schematic representation of the PB1 mini-
gene. The conservation pattern of the region is dis-
played under the diagram. The cassette exon, to-
gether with ∼250 nt of UIF and DIF sequences,
including three natural putative Fox-1/2-binding
sites in the UIF region, were inserted into intron 1 of
the human -globin gene. (D) Splicing of the PB1
minigene. See the legend for B for more details.
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disease and muscular dystrophy, according to the OMIM
database (Supplemental Table S5; McKusick 1998). There-
fore, our systematic results support and extend several
scattered observations in the literature (Kaynak et al. 2003;
Bhalla et al. 2004; The Autism Genome Project Consor-
tium 2007; Martin et al. 2007; Sebat et al. 2007). Inter-
estingly, we found that predicted Fox-1/2 targets are
more likely than expected by chance to be disease genes:
157 of 1103 predicted target genes (14.2%) are annotated
in the OMIM database as disease genes, compared with a
proportion of 7.8% for all genes (P = 8.3 × 10−14), or
10.7% for control genes with a comparable conservation
level (P = 0.0001) (Supplemental Table S7). This correla-
tion is indicative of the potential pathological impact
when conserved tissue-specific SRNs are dysregulated.
We also note that the predicted target genes also have
many more introns than the control genes (15 vs. eight,
median, according to RefSeq transcripts, P < 2.1 × 10−16,
Wilcoxon rank sum test). Disease genes tend to be more
intron-rich than average, and are thus more susceptible
to splicing dysregulation (López-Bigas et al. 2005), which
could contribute to the association between Fox-1/2 tar-
gets and OMIM phenotypes we observe.
Creation and loss of Fox-1/2-binding sites
may contribute to fine-tuning of gene expression
The large number of species included in our comparative
analysis makes it possible to study not only the conser-
vation, but also the evolutionary creation and loss of
Fox-1/2-binding sites in specific lineages. Here we
mainly analyzed the intronic sites, due to the difficulty
in decoupling the mixed selective pressures in coding
exons. About 17% of the predicted intronic binding sites
are conserved in at least one of the five fish species we
analyzed, including those in UAP1, Muscleblind-like
genes, PBX1, NLGN3, and others. In contrast, ∼19% of
the sites are conserved only in mammals. We note that
these estimates are biased, due to the artificial enrich-
ment of more conserved sites in our prediction. Never-
theless, they point to evolutionary changes in Fox-1/2
splicing regulation, which may contribute to phenotypic
differences across different species, or among different
individuals in human populations, as illustrated below.
The first example is a 34-nt exon from PTB (exon 11)
and nPTB (exon 10), which results in frame-shifting and
nonsense-mediated mRNA decay (NMD) when skipped,
and is critical for expression of full-length functional
products from both genes (Fig. 6A,C; Supplemental Fig.
S7B); Boutz et al. 2007b). Together with regulation by
microRNAs, controlled splicing of this exon through au-
toregulation switches expression from PTB to nPTB in
developing neurons, which in turn results in reprogram-
ming of the splicing patterns of their target RNAs (Boutz
et al. 2007a,b; Makeyev et al. 2007). In addition to these
negative regulators, we found that Fox-1/2 strongly acti-
vate inclusion of the nPTB exon, presumably by inter-
acting with the two DIF sites, D-I and D-II; in contrast,
the effect of Fox-1/2 on the paralogous PTB exon is more
subtle (Fig. 6A). Comparison of the two paralogs revealed
Figure 6. Creation and loss of Fox-1/2-
binding sites reflect potential fine-tuning
of gene expression after gene duplication.
(A) A 34-nt paralogous cassette exon from
PTBP1 (PTB) and PTBP2 (nPTB). For each
gene, the conservation pattern of the re-
gion is displayed under the diagram. The
two downstream conserved putative Fox-
1/2-binding sites (D-I, D-II) are labeled. Re-
sults of RT–PCR analysis are shown on
the right for each exon. For each panel, the
quantified exon inclusion level is indi-
cated. (B) A 36-nt cassette exon from
MBNL1, MBNL2, and MBNL3, shown
similarly as in A. The MBNL1 and MBNL2
exons have two copies of the Fox-1/2-bind-
ing site, one in the UIF sequences close to
the 3 splice site (U–I) and the other in the
exon (E-II). The MBNL3 exon has an addi-
tional site in the UIF sequences (U-III). For
each panel, the quantified exon inclusion
level is indicated. (C) The presence or ab-
sence of Fox-1/2-binding sites in 28 verte-
brate species for the sites labeled in A and
B. The presence of each site in each spe-
cies is color-coded and shown under the phylogenetic tree. The BLS for each site is shown on the right. For the PTB exon, site D-I
appears to be lost in placental mammals by a T-to-C mutation at the first position, resulting in a CGCAUG element, which is shown
in green. For the MBNL3 exon, site U-I is polymorphic in human and overlaps with an A/G SNP (rs3736748) at the fourth position.
(D) The allele frequency of the SNP rs3736748 in African Americans (YRI), Europeans (CEU), and Asians (HCB/JPT) was determined
according to HapMap data. The A allele (blue) results in an intact Fox-1/2-binding site and the G allele (yellow) results in a disrupted
site.
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that PTB has a T-to-C substitution at the first position of
the proximal D-I site, creating a CGCAUG element with
weaker affinity for Fox-1/2 (Fig. 6 A,C; Supplemental Fig.
S7B). The loss of UGCAUG occurred in the last common
ancestor of placental mammals, because an intact UG-
CAUG element is preserved in four nonmammalian ver-
tebrates. Such a lineage-specific alteration may have
contributed to the evolution of PTB SRNs in mammals.
The second example is a 36-nt cassette exon from three
Muscleblind-like genes, MBNL1, MBNL2, and MBNL3
(Fig. 6B,C; Supplemental Fig. S7C). We predicted and vali-
dated all three paralogous exons as Fox-1/2 targets (Fig.
6B,C). In the MBNL1 and MBNL2 exons, there are two
Fox-1/2-binding sites as putative silencers: one overlap-
ping with the polypyrimidine tract (−14 to −9, denoted as
U-I) and the other in the exonic region (12–17, denoted as
E-II). Both sites are conserved in almost all vertebrate
species we analyzed. Interestingly, the U-I site upstream
of the MBNL3 exon is polymorphic in human popula-
tions: It overlaps with an A/G SNP (rs3736748) at the
fourth position, resulting in two alleles UGC[A/G]UG,
although the site is conserved in most vertebrates. In
addition, another site (U-III) was created further up-
stream from the exon (Fig. 6B; Supplemental Fig. S7C).
Interestingly, the allele frequency of the SNP differs radi-
cally in different populations, according to HapMap data
(2 = 153, P = 6 × 10−34) (The International HapMap Con-
sortium 2007). Consequently, the Fox-1/2-binding site is
intact in most Africans (YRI), but is disrupted in most
Asians (HCB/JPT), with Europeans (CEU) somewhere in
between. We validated by direct sequencing that the U-I
site is intact in HeLa cells (African origin), which is con-
sistent with the increased exon skipping upon Fox-1/2
expression. This example provides a good model to study
how genetic variations may affect splicing regulation
and result in phenotypic differences among individuals.
In these two examples, the paralogous intronic se-
quences, especially the Fox-1/2-binding sites, can still be
aligned, despite considerable nucleotide substitutions.
We found more examples belonging to this category, in-
cluding another exon pair from MBNL1/2 (Supplemental
Fig. S7D), NLGN3/4X/4Y (Supplemental Fig. S7E), and
EBP41/41L2 (Supplemental Fig. S7F). However, this is
not always the case: In two pairs (or trios), one from
Fox-1/2 (Supplemental Fig. S7A) and the other from
ELAVL2/3/4 (Supplemental Fig. S7G), the intronic se-
quences, including the putative Fox-1/2-binding sites,
are very difficult to align. Since the Fox-1/2 sites in each
paralog are significantly conserved across vertebrate spe-
cies, the creation/loss of putative binding sites occurred
very early after gene duplication, and was then fixed in
the descendent species. Therefore, gene duplication can
be followed by splicing divergence, providing parallel
paths for producing genetic diversification.
Discussion
Extensiveness of Fox-1/2 SRNs
In this study, we used the highly conserved and related
brain-, heart-, and muscle-specific splicing factors Fox-1
and Fox-2 as a model to predict their RNA targets, and to
define and characterize their SRNs. By comprehensive
phylogenetic analysis of the specific Fox-1/2 motif in 28
vertebrate species, we predicted thousands of target ex-
ons and genes with conserved Fox-1/2-binding sites in
vertebrates. We estimate by statistical analysis that
∼76% of the predicted targets are bona fide targets, and
indeed, more than half of a set of 55 predicted targets
could be validated experimentally by manipulating Fox-
1/2 expression in HeLa cells. The extent of the SRN is
comparable with the gene regulatory networks of certain
master transcription factors (Massie and Mills 2008),
which is surprising, in light of the very limited number
of targets of splicing factors identified to date (for review,
see Li et al. 2007).
Our predictions may still represent an underestimate,
because we focused only on the conserved components
of the Fox-1/2 SRNs that can be predicted with high
specificity and sensitivity. Many additional binding sites
with a relatively low level of conservation might also be
functional, as we observed experimentally (data not
shown). Moreover, in some extreme cases, a functional
Fox-1/2-binding site can be thousands of nucleotides
away from the regulated exon (Nakahata and Kawamoto
2005); such targets would have escaped our predictions.
Furthermore, our predictions included several splicing
factors involved in brain- and/or muscle-specific splic-
ing, such as Fox-1/2, PTBP1/2 (PTB/nPTB), CUGBP1/2,
NOVA1, and MBNL1/2/3. Therefore, potential regula-
tion of these splicing factors by Fox-1/2 implies that the
Fox-1/2 SRNs are not limited to direct targets, but prob-
ably include a large number of indirect targets as well.
Our study highlights the importance of tissue-specific
splicing in diversifying gene expression regulation.
Mechanisms of Fox-1/2-dependent exon activation
and repression
The effect of splicing factors on splicing activation or
repression often depends on the location and context of
the regulatory sequences they bind. This was reported
both for ubiquitous splicing factors, such as SR proteins
(Ibrahim et al. 2005) and hnRNPs (Hung et al. 2008), as
well as for tissue-specific splicing factors (Ule et al.
2006). Nova-1/2 regulate target exon inclusion and skip-
ping in a predictable way: Downstream intronic binding
sites are usually enhancers, whereas upstream and ex-
onic binding sites are usually silencers. A similar mecha-
nism was already proposed for Fox-1/2, based on studies
of a few exons, such as ATP5C1 (F1) exon 9, fibronectin
EIIIB exon, c-src N1 exon, and EWS exon 4 (Jin et al.
2003; Underwood et al. 2005). The enhancer character of
downstream Fox-1/2 sites was confirmed on a larger
scale by several studies focusing on brain- or muscle-
specific exons (Sugnet et al. 2004; Das et al. 2007). How-
ever, the silencer character of upstream binding sites was
not obvious from these studies. Therefore, it was unclear
whether there is a general mechanism predictive of Fox-
1/2-mediated splicing patterns. Our comprehensive pre-
diction of Fox-1/2 targets, followed by unbiased experi-
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mental validation, leads to a conclusive answer: Our
analyses of splicing microarrays, and RT–PCR data in
primary tissues and in HeLa cells in the presence and
absence of Fox-1/2, very consistently demonstrate that
downstream intronic Fox-1/2 sites are potent enhancers,
whereas upstream intronic sites have the opposite effect.
More experiments are required to understand the un-
derlying mechanisms of how Fox-1/2 interact with the
spliceosome to modulate splicing. Putative Fox-1/2-
binding sites are generally more enriched in the down-
stream intron, with a distribution peak ∼30 nt from the
exon; the upstream intron shows a smaller enrichment
with a broader distribution (Yeo et al. 2007; data not
shown). Interestingly, for alternative 5 splice sites, pu-
tative Fox-1/2-binding sites show a strong preferential
location in the DIF region, whereas for alternative 3
splice sites, a more moderate enrichment in the UIF re-
gion is seen. The preferential enrichment at particular
distances downstream from 5 splice sites suggests that
Fox-1/2 might be more efficient at enhancing 5 splice
site recognition. In contrast, the mechanisms through
which Fox-1/2 block exon recognition might be more
heterogeneous. For example, in the context of hF1 gene
exon 9, Fox-1 binding to a GCAUG element in intron 8
blocks prespliceosomal E-complex formation in intron 9,
resulting in skipping of exon 9 (Fukumura et al. 2007).
We found cases (e.g., exons from Muscleblind-like genes)
in which the Fox-1/2-binding sites in the UIF region are
very close to the downstream 3 splice site. In these
cases, Fox-1/2 likely block the recognition of the intron
preceding the alternative exon by interfering with bind-
ing of spliceosomal components that recognize the poly-
pyrimidine tract, 3 splice site, and/or branch site. Fur-
thermore, for alternative exons with multiple Fox-1/2-
binding sites, these sites are not equivalent in Fox-1/2-
dependent activation or repression of exon inclusion.
Rather, the sites closer to the splice sites appear to be
more efficient than the distal sites, at least with the two
minigenes we tested. One interpretation is that Fox-1/2
proteins bound to the proximal sites are more efficient at
directly interacting with spliceosomal components.
The potential functional differences between isoforms
of Fox-1/2, as well as between the two paralogs, on target
recognition and splicing are another interesting ques-
tion. Fox-2 is reported to autoregulate its expression by
repressing the inclusion of exon 6 (Baraniak et al. 2006).
Indeed we predicted this exon as a target; in addition, we
also predicted four other exons in Fox-1, and one other
exon in Fox-2, as potential targets for autoregulation.
Among them are one of the mutually exclusive exons in
Fox-1 and its paralogous exon in Fox-2 (Supplemental
Fig. S7A). The Fox-1 exon, dubbed B40, is specifically
included in brain, whereas the other mutually exclusive
exon, M43, is specifically included in muscle (Nakahata
and Kawamoto 2005). Therefore, Fox-1/2-mediated AS of
these two exons might be important for generating dif-
ferent isoforms of Fox-1/2 proteins in different tissues,
which may in turn affect target gene splicing differently.
In terms of the comparison between Fox-1 and Fox-2,
they have similarly high expression in brain and heart/
muscle tissues, but Fox-2 is also widely expressed in
other tissues. However, because Fox-1 and Fox-2 recog-
nize the same RNA element (Jin et al. 2003; Auweter et
al. 2006; Ponthier et al. 2006), it is impossible to distin-
guish Fox-1/2 targets through their predicted binding
sites, as in the present study. Overexpression and knock-
down of Fox-1 or Fox-2 individually or together in HeLa
cells suggest that these two proteins have very similar
effects in activating or repressing predicted targets. We
expect that further insights will be gained by identifica-
tion of the in vivo targets of Fox-1 and Fox-2 experimen-
tally in the appropriate tissue types, as well as by deter-
mination of the mechanisms of action of these factors.
Complex splicing patterns suggest potential
combinatorial regulation
Overexpression and knockdown of Fox-1/2 in HeLa cells,
followed by RT–PCR analysis, demonstrated that our
predictions of Fox-1/2 targets are amenable to more de-
tailed experimental follow-up. However, the observed
validation rate was somewhat lower than our statistical
estimate, and it was not always clear why some predic-
tions were validated while the others failed. A possible
explanation is that the FDR based on permutations
might be overoptimistic, due to some type of bias; alter-
natively, some predicted Fox-1/2 sites may be present
within RNA secondary structures that make them inac-
cessible to Fox-1/2; yet another likely possibility is that
Fox-1/2 alone are not always sufficient to affect the splic-
ing pattern of a bona fide target pre-mRNA.
Both splicing microarray analysis and RT–PCR valida-
tions suggest the existence of exons with complex splic-
ing patterns that cannot be explained by Fox-1/2 regula-
tion alone. Although the effect of Fox-1/2 on splicing of
these exons is not always observable because of the dif-
ficulty in identifying the appropriate tissues or develop-
mental stages, in some cases, the requirement for other
cooperating splicing factors in Fox-1/2-mediated splicing
regulation is readily apparent. Our argument is based on
comparison of splicing patterns between brain and
muscle/heart, where Fox-1/2 are highly expressed. Using
splicing microarrays, we identified clusters of cassette
exons with inconsistent splicing patterns among these
tissues, an indication of combinatorial regulation. This
difference is especially pronounced for a cluster of DIF
site-containing exons, which are predominantly in-
cluded in muscle, as expected, but mostly skipped in
brain. One good example is the UAP1 exon, with two
downstream intronic binding sites, which was also vali-
dated by RT–PCR analysis of primary tissues and HeLa
cells. Other splicing activators or repressors might be
expressed and functional only in brain or heart/muscle,
but not in both. A similar argument might hold for HeLa
cells, which would help explain the lack of responsive-
ness of some exons to manipulating Fox-1/2 expression.
A few splicing factors that interact or have the poten-
tial to interact with Fox-1/2 have been reported recently.
For example, several additional proteins, including
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hnRNPs F/H and PTB/nPTB, are responsible for neuron-
specific splicing of the c-src N1 exon, besides Fox-1/2
(Underwood et al. 2005). The repressive activity of nPTB
in such cases could explain why some exons are skipped,
despite the presence of downstream Fox-1/2-binding
sites as potential enhancers. Alternatively, muscle-spe-
cific activators might also be important for the inclusion
of these exons in heart and muscle. Recently, one such
factor, called sup-12, was identified in C. elegans by a
genetic screen (Kuroyanagi et al. 2007). sup-12 coordi-
nately regulates tissue-specific splicing of the fibroblast
growth factor receptor gene egl-15, by binding to a
UGUGU element juxtaposed to the fox-1-binding sites.
Because this protein shows a very high level of sequence
conservation with the mammalian homologs (RBM38
and RBM24), it will be interesting to see if these mam-
malian proteins function similarly in cooperative splic-
ing regulation with Fox-1/2.
Implications of Fox-1/2 SRNs for neuromuscular
functions, disease, and evolution
This study extends previous observations and indicates
that modularity may represent a more general feature of
tissue-specific SRNs, with coregulated genes sharing
similar cellular functions (Ule et al. 2005b). Many of the
predicted target genes are known to have important neu-
romuscular functions, consistent with the exclusive or
preferential expression of Fox-1/2 in brain, heart, and
muscle tissues. For example, the list includes genes in-
volved in muscle contraction, such as a number of myo-
sin genes, dystrophin (DMD), titin (TTN), and tropomyo-
sin 1 (TPM1). Several splicing factors known to be im-
portant for neuronal and/or muscle-specific splicing are
also predicted as Fox-1/2 targets. Not surprisingly, dis-
ruption of several of our predicted target genes has
been implicated in various neuronal disorders, heart dis-
ease, and developmental defects. Among them, two neu-
roligin genes (NLGN3 and NLGN4X) are mutated in pa-
tients with X-linked autism and Asperger syndrome (Ja-
main 2003). These two genes, and another paralog,
NLGN2, have a paralogous cassette exon with a very
conserved downstream intronic Fox-1/2-binding site,
and show Fox-1/2-dependent splicing. In addition, 15
predicted target genes, including Fox-1 itself, show spo-
radic copy-number variations in autistic patients, (The
Autism Genome Project Consortium 2007; Sebat et al.
2007; X. Zhao and J. Sebat, pers. comm.). For complex
genetic diseases, sporadic mutations can be found in
many separate loci that lack apparent functional rela-
tionships. Therefore, placing the discrete disease-associ-
ated genes into a gene regulatory network can shed
light on common pathological mechanisms for these dis-
eases.
On the other hand, splicing regulatory elements, in-
cluding the Fox-1/2-binding motif, are generally short.
Creation and loss of these elements by random muta-
tions can readily occur during evolution. Not all of these
mutations would cause genetic diseases. Instead, some
of the mutations might have only moderate effects and
can therefore be tolerated. Two examples we examined
included PTB, in which a site was likely lost in all mam-
malian species, and MBNL3, in which a site was likely
lost in Asians, while being preserved in Africans. Al-
though further testing is required, these observations
suggest that tissue-specific SRNs might show consider-
able divergence between mammals and nonmammalian
vertebrates, as well as among different human popula-
tions.
Materials and methods
Compilation of exons and AS events using splicing graphs
We built a database of classified AS events (dbCASE, http://
rulai.cshl.edu/dbCASE) using high-quality transcripts (mRNA/
EST) and genome alignment (coverage > 85%, identity > 95%),
for human, mouse, rat, and other model organisms (Zhang et al.
2007). Exons, introns, and typical types of AS events were de-
tected using splicing graphs. For this study, we used 204,305
human AG-GT internal exons, with annotations of associated
AS events.
For each exon, we analyzed exonic sequences and 200-nt UIF/
DIF sequences. Multiple alignments of 28 vertebrate species
(Miller et al. 2007) were extracted using the mafFrag program
obtained from the University of California at Santa Cruz
(UCSC) genome browser (http://genome.ucsc.edu).
For each human AS event, we also tried to identify the or-
thologous AS event in mouse and rat. This was done by map-
ping the genomic coordinates of the AS region in mouse or rat
to the human genome using the tool liftOver obtained from the
UCSC genome browser. For example, for cassette exons, the
alternative exons and the two flanking exons were used for the
mapping. The mapped coordinates were then compared with
the corresponding regions of human AS events.
Evaluation of motif site conservation
We focused on Fox-1/2 targets with UGCAUG present in hu-
man, unless explicitly mentioned. A BLS approach (Stark et al.
2007) was adapted to measure Fox-1/2-binding site conserva-
tion, using the multiple alignment and phylogenetic tree of 28
vertebrate species (Miller et al. 2007). Briefly, the BLS of each
unique Fox-1/2-binding site (in the same alignment columns) is
the total branch length of the phylogenetic tree over which the
site is conserved, normalized by the total branch length of the
tree spanning all species. We allowed no movement of the sites
in the assignment of orthologous sites, given the high-specific-
ity and conservation of Fox-1/2-binding sites. However, in some
instances, small insertions/deletions interrupt some sites,
partly due to artifacts in sequence alignment (e.g., TGCATGG
aligned with TGCAT-G); such indels were tolerated. Therefore,
our approach is more restrictive than the original approach
(Stark et al. 2007), because we sought to trace the history of each
individual site.
To determine the significance of motif site conservation, we
estimated the null distribution of BLS using 50 random motifs
generated by permutations. Random motifs containing CpG or
GCAUG were avoided, because CpGs are underrepresented in
vertebrate genomes, and the GCAUG element is at least par-
tially functional for Fox-1/2-mediated splicing (Jin et al. 2003).
The same analysis was repeated for each of the random motifs
and motif sites to calculate BLS scores. We tried different BLS
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thresholds from 0 to 1, with steps of 0.01 to determine an ap-
propriate threshold for Fox-1/2 target prediction. For each
threshold, a FDR was calculated by the ratio of the average
number of sites with a BLS greater than the threshold for ran-
dom motifs to that for the Fox-1/2 motif.
Experimental validation of predicted Fox-1/2 targets
From the list of predicted targets, we chose to test genes in-
volved in gene expression regulation, such as transcription and
RNA processing, and with links to genetic diseases, but others
were also selected at random. Human tissue total RNAs were
purchased from Clontech. Two shRNAs against human Fox-2
were cloned into the MSCV retroviral vector as described (Dick-
ins et al. 2005). Human Fox-1 cDNA (NM_018723) was cloned
into the pWZL-hygro retroviral vector to express Flag-tagged
Fox-1 protein.
To generate stable cell pools, HeLa cells were infected with
MSCV (expressing the shRNA against Fox-2), or MSCV plus
pWZL-hygro (expressing Fox-1 protein) vectors. We replaced the
medium 24 h after infection, and 24 h later, infected cells were
selected with puromycin (2 µg mL−1) for 72 h. In the case of
double infection, cells were treated with hygromycin for 96 h
after selection with puromycin. The effect of knockdown or
overexpression was confirmed by Western blotting using anti-
bodies against human Fox-1 (donated by S. Powers and D. Mu)
and Fox-2 (Bethyl Laboratories, Inc.), respectively. Total RNA
was extracted from the stable cell pools using Trizol reagent
(Invitrogen) and treated with DNase I. Reverse transcription
was carried out using SuperScript II reverse transcriptase as de-
scribed by Invitrogen. Semiquantitative PCR using Taq poly-
merase was performed by adding 0.1 µL of [-32P]-dCTP to each
25-µL reaction. The PCR reactions were run for 20–25 cycles
depending on the abundance of the targets. The products were
analyzed on a 6% native polyacrylamide gel. The primer se-
quences used for validation are shown in Supplemental Ta-
ble S7.
The FMNL3 minigene was cloned into the pcDNA3.1 vector.
QuickChange PCR mutagenesis was carried out to generate the
mutant constructs. Fugene 6 was used for transfection and RT–
PCR analysis was done as above. The PB1 minigene was gener-
ated by inserting a PCR fragment containing the cassette exon
plus 243-nt UIF and 253-nt DIF sequences, into intron 1 of the
human -globin gene, using BglII and XhoI sites introduced by
site-directed mutagenesis.
Splicing microarrays
We identified exons, exon junctions, and AS events in the hu-
man genome by mapping RefSeqs, mRNAs, ESTs, and tran-
scripts from patent databases to the genome. For each gene,
60-nt probes and 36-nt probes were optimized to monitor exons
and exon junctions, respectively, and printed on Agilent arrays.
These arrays were used to monitor 47 diverse human tissues
and cell lines in dye-swap replicates (Supplemental Table S3).
Gene expression levels were estimated from probes monitoring
constitutive exons and junctions. For each AS event, a propor-
tional change of isoform abundances, relative to a reference
pool, was then estimated by adapting a previous method (Ule et
al. 2005b). More detailed information and data availability will
be described elsewhere (J.C. Castle, C. Zhang, J.K. Shah, A.V.
Kulkarni, T.A. Cooper, and J.M. Johnson, in prep.). The raw and
processed microarray data, as well as additional information, are
available at GEO (http://www.ncbi.nlm.nih.gov/geo, under ac-
cession GSE11863) and on our Web site (http://rulai.cshl.edu/
Rosetta_AS_supp/index.html) for download, and in dbCASE in
a searchable form.
GO term and OMIM phenotype analyses
The GO term analysis was performed using the online tool
DAVID (Dennis et al. 2003). DAVID gives a P-value, before and
after multiple-test corrections, based on a modified hypergeo-
metric distribution. We used a background set of 15,040 genes,
controlling for the conservation level. More specifically, a gene
was included in the control gene set if at least one of its exons
has a consecutive hexanucleotide with a BLS greater than a
specified threshold (BLS  0.22 for UIF and DIF sequences and
BLS  0.8 for exonic sequences). The OMIM phenotypes and
associated genes were downloaded in December, 2007 (McKu-
sick 1998).
Statistical analysis
Fisher’s exact test in the software package R (http://www.
r-project.org) was used to evaluate the significance of two-by-
two contingency tables.
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